Dr. Brian Kelly (Purdue University, West Lafayette, Indiana) discusses a study that found recent efforts to curb opioid prescriptions appear to have had an effect on reducing prescription opioid misuse and dependence, with no evidence that shifts in local-level opioid dispensing affected odds of heroin use, frequency of heroin use, or heroin dependence. Afterwards, Journal Editor-in-Chief Dr. Ned Kalin discusses what pulls the March issue of AJP together. Kelly interview [00:30] Why county...

Dr. Giovanna Punzi and Dr. Daniel Weinberger (Lieber Institute for Brain Development, Baltimore, Maryland) discuss findings from their new paper, “Genetics and Brain Transcriptomics of Completed Suicide,” which looks at differences in the brains of those who die by violent versus less violent means of suicide.  Afterwards, Journal Editor-in-Chief Dr. Ned Kalin discusses what pulls the March issue of AJP together. Punzi and Weinberger interview [00:43] What made the two categories distinct?...

Dr. Margaret Sibley (University of Washington, Seattle, WA) joins the podcast this month to discuss an article from the February issue of the Journal looking at patterns of remission in attention deficit hyperactivity disorder in children.  Dr. Ned Kalin, Editor-in-Chief of AJP will join us afterwards to discuss the rest of the February issue of the Journal. Sibley interview [00:51] What does “full remission” from ADHD mean? [01:54] Variable patterns of remission in children with ADHD...

In this month’s AJP Audio, Dr Margert Haney (Director of the Cannabis Research Laboratory at Columbia Psychiatry) discusses her new review from the January issue of the American Journal of Psychiatry, “Cannabis Use and the Endocannabinoid System: A Clinical Perspective,” and the questions around the legal status of cannabis research. Afterward, Dr. Ned Kalin, Editor-in-Chief of the Journal discusses the January 2022 issue of AJP.

In this month’s AJP Audio, Dr. Samuel Wilkinson (Yale University, Associate Director of the Yale Depression Research Program) discusses a study looking at the association of electro-convulsive therapy or ECT on all-cause mortality and suicide in Medicare patients with mood and bipolar disorders. Following that, Dr. Ned Kalin, Editor-in-Chief of the Journal discusses the December issue of AJP.

Dr. Jennifer Stevens (Assistant Professor of Psychiatry and Behavioral Sciences, Emory University) discusses a technique to classify trauma victims into discrete biotypes in the immediate aftermath of trauma, with the hope of providing insight into the groups that could guide treatment, and American Journal of Psychiatry Editor-in-Chief Dr. Ned Kalin puts the November, 2021 issue of AJP into context.

Executive Editor Michael Roy speaks with Lara N. Coughlin, Ph.D., and Lewei Allison Lin, M.D., M.S., about their article on the provision of guideline-concordant depression treatment to patients with and without substance use disorders (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.20040454).

Executive Editor Michael Roy speaks with Karen L. Bierman, Ph.D., about her article on reducing adolescent psychopathology in socioeconomically disadvantaged children with a preschool intervention (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.20030343).

Executive Editor Michael Roy speaks with Glenn Verner, M.P.H., and Sonja Entringer, Ph.D., about their article on the relationship between maternal psychological resilience during pregnancy and newborn telomere length (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.19101003).

Executive Editor Michael Roy speaks with Luke J. Norman, Ph.D., and Kate D. Fitzgerald, M.D., about their article examining whether brain activity is associated with treatment response to cognitive-behavioral therapy in adolescents and adults with obsessive-compulsive disorder, and whether any associations are treatment specific relative to an active control psychotherapy (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.19080886).

Executive Editor Michael Roy speaks with American Journal of Psychiatry Editor-in-Chief Ned H. Kalin, M.D., and Deputy Editor Carolyn Rodriguez, M.D., Ph.D., about the Journal’s response to COVID-19; strategies to combat racism, social injustice, and health care inequities (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.20071051); research highlights from the past year; and what lies ahead in 2021.

Executive Editor Michael Roy speaks with Sara K. Blaine, Ph.D., and Rajita Sinha, Ph.D., about their article on the use of brain imaging in the evaluation of drinking outcomes during early outpatient treatment for alcohol use disorder (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.19070703).

Executive Editor Michael Roy speaks with Constance Guille, M.D., and Richard F. Summers, M.D., about their article on the prevalence of burnout and depressive symptoms among North American psychiatrists (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.19090901). A related commentary on burnout by Dr. Summers also is discussed (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.19090902).

Executive Editor Michael Roy speaks with Emily Robertson, M.A., and Paul Frick, Ph.D., about their article on the role that callous-unemotional traits have in the risk for gun carrying and gun use during a crime (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.19080861).

Executive Editor Michael Roy speaks with Jennifer Dwyer, M.D., Ph.D., and Awais Aftab, M.D., about the physiology of three major endocrine systems and about the evidence for hormone-based interventions in the treatment of major depressive disorder (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.19080848).

Executive Editor Michael Roy speaks with Stéphane Potvin, Ph.D., and Alexandre Dumais, M.D., Ph.D., about their meta-analysis investigating the association between cannabis use and violence, and, more specifically, the perpetration of any type of physical violence by adolescents and young adults (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.19101008).

Executive Editor Michael Roy speaks with Katherine MacDuffie, Ph.D., and Annette Estes, Ph.D., about their longitudinal neuroimaging study examining associations between sleep difficulties and developmental trajectories among infants who go on to develop autism spectrum disorder (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2019.19060666).

Executive Editor Michael Roy speaks with Collin Reiff, M.D., and William McDonald, M.D., about their evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders (https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2019.19010035).

Executive Editor Michael Roy speaks with Sarah A. Sullivan, Ph.D., and Stanley Zammit, Ph.D., about their research on the incidence, course, and outcome of psychotic experiences from childhood through early adulthood in the general population, and the prediction of psychotic disorder.

Executive Editor Michael Roy speaks with Damiaan Denys, M.D., Ph.D., and Ilse Graat, M.D., about their research on the tolerability and effectiveness of deep brain stimulation for patients with refractory obsessive-compulsive disorder.

Executive Editor Michael Roy speaks with Arthur Robin Williams, M.D., M.B.E., and Mark Olfson, M.D., M.P.H., about their research on adverse health outcomes following discontinuation of buprenorphine among Medicaid beneficiaries who were retained for variable periods beyond 6 months.

Executive Editor Michael Roy speaks with Younga H. Lee, Ph.D., and Stephen L. Buka, Sc.D., about their research on the association between maternal bacterial infection during pregnancy and risk for psychotic disorders in offspring.

Executive Editor Michael Roy speaks with Antonia Kaczkurkin, Ph.D., and Theodore Satterthwaite, M.D., about their research on how different measures of brain structure (cortical thickness and volume) in youths are associated with various dimensions of psychopathology.

Executive Editor Michael Roy speaks with Yasmin Hurd, Ph.D., about her research on the potential of cannabidiol (CBD) to reduce cue-induced craving and anxiety, two critical features of addiction that often contribute to relapse and continued drug use, in drug-abstinent individuals with heroin use disorder.